Neurology & Mental Health

A Blood Test's Blind Spots: Discrepancies Between P-tau217 and Clinical Alzheimer's Disease

George Padron
Precision Medicine, Biomarker & Genomic Testing, Neurology & Mental Health, Alzheimer's & Dementia | Aug 1, 2026
P-tau217 was identified as the strongest blood marker for clinical Alzheimer's disease in a study of 1,817 Caribbean Hispanic adults; however, 37% of diagnosed patients tested negative.

Study Finds Parkinson's Genetic Yield Varies from 0.4% to 10.7% Based on Ancestry

Sonia Reyes
Healthcare Headlines, Neurology & Mental Health, Movement Disorders, Access & Affordability, Coverage & Appeals, Managed Care, Population Health Management, Clinical Trial Updates | Jul 18, 2026
A GP2 study finds that the yield of Parkinson's gene panels varies by ancestry, and European-built panels are not transferable.

Head-to-Head Trial Compares Low-Cost MS Drug to Brand Drug

George Padron
Neurology & Mental Health, Multiple Sclerosis, Clinical Trial Updates | Jul 8, 2026
OVERLORD-MS, the first randomized head-to-head trial, finds low-cost off-label rituximab noninferior to ocrelizumab on MRI activity in newly diagnosed relapsing MS.

Cognitive Outcomes Separate Two AR Inhibitors in Direct Comparison

Sonia Reyes
Oncology Care, GU Cancers, Neurology & Mental Health, Alzheimer's & Dementia | May 30, 2026
ASCO 2026 ARACOG: darolutamide showed less 24-week cognitive decline than enzalutamide in advanced prostate cancer, with all 30 crossovers moving toward darolutamide.

Self-Administered Nanobody for Myasthenia Gravis Shows Phase 3 Efficacy

Sonia Reyes
Neurology & Mental Health, Rare Neurological Diseases | Apr 23, 2026
Gefurulimab, a once-weekly self-administered subcutaneous nanobody for gMG, met phase 3 PREVAIL endpoints at Week 26, potentially shifting care away from IV infusion centers.